Skip Navigation Links

Past Studies

These research studies have been completed.

ApoE Genotypes in Stroke Recovery

Principal Investigators: Greenberg, Steven, M.D., Ph.D., Furie, Karen, M.D., and Stein, Joel, M.D.
Start Date: November 1999
End Date: October 31, 2003

Online Publications

AVAIL

Adherence eValuation After Ischemic Stroke Longitudinal Registry

Principal Investigator: Lee H. Schwamm, M.D.
Co-Investigator: Masrur, Shihab, M.D.
Enrollment: Shihab Masrur 617.724.4941
Start Date: Under IRB review
End Date: December, 2007 for recruitment

Summary: AVAIL is a prospective, observational study for the hospitals participating in Get With the Guidelines-Stroke Program with the study aims to describe longitudinal treatment patterns and patients’ downstream clinical and functional outcomes among a broad community-based population.

Cost effectiveness of novel stroke therapy

Principal Investigators: Gazelle, Scott, M.D., Ph.D., Furie, Karen, M.D., Gleason, Suzanne, Ph.D., and Koroshetz, Walter J., M.D.

Summary: Center for Innovative and Minimally Invasive Therapy/ Department of Defense funded study of the cost of stroke and the benefit that may accrue from new therapies to reduce disability.

Publications

DIAS-2 (Desmoteplase (INN) in Acute Ischemic Stroke): PHASE 3 Clinical Trial

Principal Investigator: Schwamm, Lee H., M.D.
End Date: January 2007

Summary: DIAS-2 was a prospective, randomized, double-Blind, placebo-Controlled, single Bolus, multinational, multicenter, parallel group, dose-ranging study of desmoteplase (INN) in the indication of acute stroke. Massachusetts General Hospital was the participating site for this trial and was a highest enrolling site in North America.

Online Publications

Effects of Normobaric Oxygen Therapy in Ischemic Stroke

Normobaric Hyperoxia in Acute Ischemic Stroke

Funded by: NIH / NINDS

Principal Investigator: Singhal, Aneesh B., M.D.

Summary: This translational research project comprises several rodent studies and a 150-patient stroke clinical trial being conducted in conjunction with the SPOTRIAS project listed below [Clinicaltrials.gov Identifier: NCT00414726]. The overall goal is to investigate the safety, efficacy, and therapeutic mechanisms of normobaric oxygen therapy (NBO) in acute ischemic stroke. A major component of this research involves the use of state-of-the-art MRI technology to understand the mechanisms underlying oxygen's effects.

Online Publications

  • None available

Effect of Surgery-Related Brain Hypoperfusion on ß-Amyloid Deposition

NIH-NIA National Institute on Aging/ADRC

Principal Investigator: Greer, David M., M.D.
Co-Investigators: Dr. Steven M. Greenberg, Dr. Jonathan Rosand and Dr. Anand Viswanathan
Enrollment: Amy Halpin 617.643.2782
End Date: March 31, 2010

Summary: The goal of this project is to determine the effect of surgery-related circulatory arrest on cerebral PiB retention and plasma Aß concentration, and to correlate surgery-related changes in PiB-PET imaging or plasma Aß with changes in brain structural neuroimaging or cognitive performance.

Extended-release dipyridamole/G-tube trial

Pharmacokinetics of extended-release dipyridamole following administration through gastric tubes

Funded by: Boehringer Ingelheim Pharmaceuticals, Inc.

Principal Investigator: Greer, David M., M.D.
Co-Investigator: Crandell, David, M.D.
Research Assistant: Batista, Leonardo, M.D., D.D.S.
Enrollment: Closed to Enrollment
Start Date: November 2005
End Date: August 27,2009

Summary: The purpose of this pilot study is to evaluate dipyridamole serum concentrations obtained following administration of extended-release dipyridamole through gastric tubes, compared with serum concentrations obtained through oral administration.  After completion of this study, the data will provide information regarding the utility of gastric tubes as a possible route of administration of extended-release dipyridamole.

Families in Recovery from Stroke (FIRST)

Principal Investigators: Furie, Karen, M.D. and Kistler, Philip, M.D.

Summary: NIH sponsored randomized double-blind placebo-controlled trial of family intervention in stroke recovery.

Online Publications

FLO24

Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients

Principal Investigators: Nogueira, Raul G., M.D.and Almozlino, Avraham, M.D.
Co-Investigators: Buonanno, Ferdinando S., M.D., Carandang, Raphael, M.D., Gonzalez, Ramon, M.D.,Greer, David M., M.D., Hirsch, Joshua, M.D., Hochberg, Leigh R., M.D., Ph.D., Leesch, Wolfgang, M.D., Masrur, Shihab, M.D., Muehlschlegel, Susanne, M.D., Park, Soojin, M.D., Potter, Nicholas S., M.D., Ph.D., Pryor, Johnny, M.D., Rabinov, James, M.D., Rordorf, Guy A., M.D., Rosand, Jonathan, M.D., MSc, Rost, Natalia S., M.D., Schwamm, Lee H., M.D., Sheth, Kevin, M.D., Silverman, Scott, M.D., Sims, John R., M.D., Smith, Eric E., M.D., Strozyk, Dorothea, M.D., Thompson, Bradford, M.D., Viswanathan, Anand, M.D., Ph.D., Yoo, Albert, M.D.
Enrollment: Shihab Masrur 617.724.4941
Start Date: August 13, 2007
End Date: Please contact us for this information

Summary: To assess the safety and feasibility of the NeuroFlo catheter in treating patients with ischemic stroke whose last known time symptom-free was between 8-24 hours prior to treatment. The study is a prospective, single arm treatment feasibility trial to determine the baseline safety and feasibility of the NeuroFlo device in acute ischemic stroke patients whose last known time symptom free is between 8 and 24 hours.

Abstract: Not yet available

IMS III

Interventional Management of Stroke: PHASE 3 Clinical Trial

Principal Investigator: Lee H. Schwamm, MD
Co-Investigators: Buonanno, Ferdinando, M.D., Greer, David, M.D., Hirsch, Joshua, M.D., Hochberg, Leigh, M.D., Muehlschlegel, Susanne, M.D., Nogueira, Raul, M.D., Park, Soojin, M.D., Pryor, Johnny, M.D., Rabinov, James, M.D., Rordorf, Guy, M.D.,Rosand, Jonathan, M.D., Rost, Natalia, M.D., Silverman, Scott, M.D., Sims, John, M.D., Smith, Eric, M.D., Thompson, Bradford, M.D., Viswanathan, Anand, M.D.
Enrollment: Shihab Masrur 617.724.4941
Start Date: IRB approved for 2007
End Date: December 21, 2010

Summary: IMS 3 is a randomized, multi-center, open label trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase®) alone when initiated within three hours of acute ischemic stroke onset.

NIH study of stroke progression by advanced MRI techniques

Principal Investigators: Gregory Sorensen, M.D. and Aneesh B. Singhal, M.D.
Enrollment: Aneesh B. Singhal, M.D. 617.726.8459
Start Date: April 23, 1999
End Date: March 31, 2009

Summary: Using diffusion weighted and perfusion MR imaging to map out the growth of stroke injury over the first hours to days in patients with ischemic stroke. The goal is to construct a predictive model of eventual infarct based on the acute MRI scan. This will allow precise testing of therapeutic strategies.

Inclusion/Exclusion Criteria

P300-BCI

P300 Brain-Computer Interface

Funded By: Department

Principal Investigator: Hochberg, Leigh R., M.D., Ph.D.
Start Date: January 9, 2007
End Date: January 9, 2009

Summary and Online Publications

  • None available

PET Imaging of Cerebral Amyloid Angiopathy with Pittsburg Compound B

Alzheimer’s Association

Principal Investigator: Dr. Steven M. Greenberg
Co-Investigators: Dr. Keith Johnson, Dr. Jonathan Rosand, and Dr. Anand Viswanathan
Enrollment: Amy Halpin 617.643.2782
Start Date: August 1, 2006
End Date: Jan. 1, 2010

Summary: The goal of this study is to determine whether CAA can be detected by PET scans using the Aß-detecting compound Pittsburg Compound B (PiB).

PET Imaging with Pittsburg Compound B and Subcortical Small Vessel Disease

Harvard Center for Neurodegeneration and Repair

Principal Investigator: Smith, Eric E., M.D.
Co-Investigators: Johnson, Keith, M.D. and MGH Dept. of Radiology
Enrollment: Amy Halpin 617.643.2782
Start Date: April 1, 2007
End Date: April 2008

Summary: Investigation of the relationships between WMH and beta-amyloidoses (AD and CAA) using PET imaging with Pittsburgh Compound B (PET-PIB) as a marker of deposited beta-amyloid.

PROFESS

Prevention Regimen For Effectively avoiding Second Strokes

Sponsor: B-1

Principal Investigator: Greer, David M., M.D.
Co-Investigators: Furie, Karen L., M.D. and Singhal, Aneesh B., M.D.

Summary: Prevention Regimen for Effectively avoiding Second Strokes (PRoFESS) is a secondary stroke prevention study looking at the effects of Aggrenox versus Plavix, with and without Micardis.

Online Publications

  • None available

Role of hypertensive therapy in ischemic stroke

Principal Investigator: Rordorf, Guy A., M.D.

Summary: Study of efficacy of induced hypertension to improve neurologic deficit in acute stroke patients by increasing brain blood flow.

Online Publications

SPOTRIAS

Specialized Program of Translational Research in Acute Stroke

Principal Investigator: Karen L. Furie, M.D.
Co-Investigators: Project 1 - Aneesh B. Singhal, M.D., Project 2 - Michael Lev, M.D., and Project 3 - Karen L. Furie, M.D.
Enrollment: Allison Dipietro 617.724.1538
Start Date: January, 2007
End Date: October, 2011

Summary: The overall goal of SPOTRIAS is to allow researchers to enhance and initiate translational research that ultimately will benefit individuals with stroke.

For more information, visit our SPOTRIAS main page or one of the following related pages:

  • Project 1: Oxygen Therapy in Acute Stroke
  • Project 2: IMPACT – Infarct Modeling through Perfusion Assessment by CT
  • Project 3: Biomarker Trial

Stroke Database / Research Registry

Principal Investigator: Karen L. Furie, M.D.
Co-Investigator: MGH Stroke Service
Enrollment: Allison DiPietro
Start Date: 1999
End Date: Ongoing

Summary: The stroke database is a prospective observational study. The inclusion criteria is any patient admitted to the MGH or BWH with TIA (transient ischemic attack); or ischemic stroke. There are no exclusion criteria. The purpose is to assess the efficacy of acute stroke interventions with respect to functional outcome and mortality in patients with acute ischemic stroke, to determine the efficacy and cost-effectiveness of stroke treatments for acute ischemic, and to create a database of stroke patients for use in ongoing research on stroke diagnosis, treatment and outcomes.

SWISS

Siblings with Ischemic Stroke

Principal Investigator: Karen L. Furie, M.D.
Enrollment: Mikaela Larson 617.643.3952
Start Date: 2005
End Date: August 1, 2008

Summary: This study is enrolling patients who have had a stroke and have a sibling with a history of stroke in order to better understand the genetics of ischemic stroke.

Abstract: Not yet available

Vascular Dysfunction in Cerebral Amyloid Angiopathy

NIH / NIA

Principal Investigator: Dr. Steven M. Greenberg
Co-Investigators: Dr. Jonathan Rosand and Dr. Anand Viswanathan
Enrollment: Amy Halpin 617.643.2782
Start Date: September 15, 2005
End Date: May 31, 2010

Summary: The major goal of this project is to analyze the effect of cerebral amyloid angiopathy on microvascular function, white matter disease, and cognitive impairment.

Thank you for e-mailing this page.

Your Name 
Your E-mail 
Friend's Name 
Friend's E-mail 
Message

Thank you for your providing feedback. Your comments will be responded to within an appropriate time frame.

Your Name 
Email 
Organization
Subject 
Message

Text Size: A A A

Bookmarking Tools

Save & Share this webpage

Digg Reddit Google Yahoo del.icio.us

In the News

The MGH Neurology Department placed 4th in US News Neurology / NeuroSurgery rankings for 2014-15.

Educational Video

Still from the Stroke Evaluation simulation

This video simulation of an Emergency stroke evaluation illustrates the care of patients with acute stroke by the MGH Acute Stroke team.